SLS Stock Today Surges 281%
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival for acute myeloid leukemia (AML) patients treated with the company's investigational therapy. The move marks one of the largest single-day gains in the stock's history and reflects investor reaction to the first late-stage survival win for the program. Watchers will focus on the full data set, regulatory filing timelines and any partnership or financing implications stemming from the readout.
Muhabbit's AI wrote this summary in its own words from Coinpedia's report. It can get details wrong, so check the source.
Named in this story
SELLAS Life Sciences, REGAL trial, acute myeloid leukemia, NASDAQ